MAAT PHARMA news, videos and press releases
For more news please use our advanced search feature.
MAAT PHARMA - More news...
MAAT PHARMA - More news...
- CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
- MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
- MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease
- MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
- MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
- MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results
- MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in aGvHD
- MaaT Pharma Joins Microbiome Therapeutics Innovation Group
- MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
- MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
- MaaT Pharma Announces New Appointments to the Board and Executive Team
- MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
- MaaT Pharma Announces Combined General Meeting on June 19, 2023 and the Availability of the Preparatory Documents
- MaaT Pharma Announces Cash and Revenues for the First Quarter of 2023
- MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
- MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
- MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting
- MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
- MaaT Pharma Announces 2022 Annual Results and Provides a Business Overview
- MaaT Pharma Receives Two Clinical Trial Application Authorizations to Evaluate MaaT033 in Two Therapeutic Indications in Europe
- Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
- Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
- MaaT Pharma Receives U.S. FDA Response Outlining Path Forward for Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease and Reports Cash and Revenues for Fourth Quarter 2022
- MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux
- MaaT Pharma Provides Corporate Update and Highlights Key Expected Milestones in 2023
- CORRECTING and REPLACING: MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
- MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
- MaaT Pharma : Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
- MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting
- MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting
